艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADC 艾格里房产

六月节休市 06-18 16:00:00 EDT

73.25

-0.56

-0.76%

盘后73.38

+0.13+0.18%

19:04 EDT

最高74.33	最低72.99	成交量183.01万
今开73.86	昨收73.81	日振幅1.82%
总市值87.92亿	流通市值79.38亿	总股本1.20亿
成交额1.34亿	换手率1.69%	流通股本1.08亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房产","latestPrice":73.25,"timestamp":1781812800000,"preClose":73.81,"halted":0,"volume":1830107,"hourTrading":{"tag":"盘后","latestPrice":73.38,"preClose":73.25,"latestTime":"19:04 EDT","volume":161748,"amount":11848052.157676,"timestamp":1781823846691,"change":0.13,"changeRate":0.001775,"amplitude":0.001775},"delay":0,"changeRate":-0.007587047825497931,"floatShares":108366822,"shares":120028300,"eps":1.85165,"marketStatus":"六月节休市","change":-0.56,"latestTime":"06-18 16:00:00 EDT","open":73.86,"high":74.33,"low":72.99,"amount":134386376.654695,"amplitude":0.018155,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.85165,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":73.81,"dividendRate":0.042425,"preHourTrading":{"tag":"盘前","latestPrice":74.3,"preClose":73.825,"latestTime":"09:24 EDT","volume":76,"amount":5623.389719999999,"timestamp":1781789048966,"change":0.475,"changeRate":0.006434,"amplitude":0.011134},"postHourTrading":{"tag":"盘后","latestPrice":73.38,"preClose":73.25,"latestTime":"19:04 EDT","volume":161748,"amount":11848052.157676,"timestamp":1781823846691,"change":0.13,"changeRate":0.001775,"amplitude":0.001775},"volumeRatio":1.2992087358791908,"impliedVol":0.2948,"impliedVolPercentile":0.9681},"requestUrl":"/m/hq/s/ADC","defaultTab":"news","newsList":[{"id":"2642250194","title":"港股异动 | 君实生物(01877)涨超5% 近日拟入股上海致域生物医药 布局ADC与多特异抗体研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2642250194","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642250194?lang=zh_cn&edition=full","pubTime":"2026-06-12 15:07","pubTimestamp":1781248026,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，君实生物涨超5%，截至发稿，涨4.67%，报17.26港元，成交额6560.03万港元。消息面上，近日，君实生物发布公告，公司拟与苏州众合、君实工程、苏州君盟、合资公司上海致域生物医药有限公司及姚盛博士订立合资协议，据此，转让方有条件同意向合资公司授予许可知识产权的一项许可，用于许可产品的研究、开发、制造、使用及商业化；向合资公司转让有形资产；及向合资公司转让IP权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399441","BK1583","BK4588","BK4080","XBI","BK1161","VXUS","BK1515","BK4585","161726","ADC","BK4231","BK4581","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642237365","title":"基石药业-B(02616)：CS5007(EGFR/HER3双特异性ADC)全球多中心I期临床试验启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2642237365","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642237365?lang=zh_cn&edition=full","pubTime":"2026-06-12 06:10","pubTimestamp":1781215804,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，本公司管线2.0核心候选药物CS5007的全球多中心I期临床试验，已正式获得澳大利亚人类研究伦理委员会的许可。这不仅标志着CS5007的全球临床开发全面启动，更意味着本公司管线2.0战略正加速兑现，后续重磅力量已进入临床快车道，有望为中长期增长持续注入信心。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK1161","02616","BK4231","BK1574","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642280708","title":"Immunome宣布IM-1617 ADC一期临床完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2642280708","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642280708?lang=zh_cn&edition=full","pubTime":"2026-06-11 22:26","pubTimestamp":1781187960,"startTime":"0","endTime":"0","summary":"生物技术公司Immunome周三宣布，其潜在首创新药抗体偶联药物IM-1617的一期临床试验已完成首例患者给药。该药物针对一种未公开的实体瘤靶点，用于治疗晚期实体瘤患者。　　IM-1617是一款靶向实体瘤的抗体偶联药物，其靶向的是一种促进肿瘤细胞存活并介导免疫细胞排斥的受体酪氨酸激酶。该药物搭载了Immunome专有的拓扑异构酶I抑制剂HC74作为有效载荷。公司计划分别于2026年中和2026年末提交另外两款抗体偶联药物IM-1340和IM-1335的新药临床试验申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-11/doc-inicaenm0622024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4080","ADC","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640153816","title":"信达生物(01801): IBI343(CLDN18.2 ADC)治疗晚期胃癌的新药上市申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640153816","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640153816?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:34","pubTimestamp":1780562045,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，IBI343用于晚期胃癌人群的国际III期临床研究按预设方案完成第一次期中分析，达到主要研究终点，IBI343在晚期胃癌治疗中展现出了卓越的疗效和良好的安全性和耐受性。基于这一积极的临床结果，公司已向中国国家药品监督管理局递交IBI343的新药上市申请。IBI343是全球首个获监管审评受理的CLDN18.2靶向ADC药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450109.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","LU2328871848.SGD","BK4080","LU2097828714.EUR","LU2242644610.SGD","BK1583","01801","LU2097828631.EUR","LU2488822045.USD","BK1589","LU1969619763.USD","LU2097828557.USD","IPOS","LU2097828805.USD","LU0455707207.USD","LU0502904849.HKD","LU2097828474.EUR","BK1161","BK4231","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640140982","title":"中国生物制药双创新药闪耀ASCO：肺癌一线疗法PFS显著延长，全球首个EGFR/c-Met双抗ADC临床数据亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2640140982","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640140982?lang=zh_cn&edition=full","pubTime":"2026-06-01 09:47","pubTimestamp":1780278420,"startTime":"0","endTime":"0","summary":"6月1日，中国生物制药（01177）发布公告，旗下附属公司正大天晴药业集团股份有限公司两项重磅创新药临床研究数据，于2026年美国临床肿瘤学会（ASCO）年会正式公布，涵盖肺癌一线治疗与全球首个EGFR/c-Met双抗ADC两大领域，疗效与安全性数据双双亮眼，彰显公司在肿瘤创新药领域的硬核实力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013755509132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4080","ADC","01177","IE00BZ08YR35.GBP","BK1521","BK1574","06978","BK4195","BK1191","BK1161","BK4231","PFS","BK4211","BK1589","BK1515","IE00BZ08YT58.USD","HK0000165453.HKD","159992","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640398600","title":"中国生物制药(01177)：TQB6411“EGFR/C-MET ADC”于2026 ASCO公布I期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2640398600","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640398600?lang=zh_cn&edition=full","pubTime":"2026-06-01 06:53","pubTimestamp":1780267985,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药TQB6411“EGFR/ c-Met ADC”于2026年美国临床肿瘤学会  大会上公布在晚期实体瘤患者中的首次人体I期临床研究数据。研究表明，TQB6411在有效剂量下呈现良好的安全性特征，尤其是血液学毒性较低。作为全球首批公布临床数据的EGFR/c-Met ADC，TQB6411凭借成熟的靶点组合及偏向c-Met端的亲和力设计，在降低研发风险的同时构建了差异化竞争优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448217.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","IE00BZ08YT58.USD","LU1989772923.USD","01177","BK4585","IE00BZ08YR35.GBP","BK1191","HK0000165453.HKD","BK4080","BK4162","LU1989772840.SGD","LU1989771016.USD","LU1291159041.SGD","LU1496350502.SGD","BK1521","IE00BZ08YS42.EUR","BK1515","BK4231","MET","BK1589","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640798605","title":"中国生物制药(01177)：维特柯妥拜单抗“CLDN18.2 ADC”于2026 ASCO公布一线胃癌II期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2640798605","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640798605?lang=zh_cn&edition=full","pubTime":"2026-06-01 06:47","pubTimestamp":1780267642,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团全资附属公司礼新医药科技(上海)有限公司自主研发的创新药维特柯妥拜单抗“CLDN18.2 ADC”于2026年美国临床肿瘤学会  大会上公布一线治疗胃或胃食管交界部腺癌的II期临床研究数据。结果显示，LM-302联合PD-1单抗  在CLDN18.2阳性晚期胃或胃食管结合部腺癌一线治疗中展现出令人鼓舞的抗肿瘤活性和可管理的安全性。治疗期间不良事件导致剂量降低的比例分别为17.9%和43.8%，导致治疗终止的比例分别为 23.1%和31.3%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","BK1191","BK4231","BK1521","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK4080","01177","BK1515","IE00BZ08YS42.EUR","BK1589","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639988885","title":"科伦博泰研究成果发表于《柳叶刀》主刊","url":"https://stock-news.laohu8.com/highlight/detail?id=2639988885","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639988885?lang=zh_cn&edition=full","pubTime":"2026-05-31 19:07","pubTimestamp":1780225625,"startTime":"0","endTime":"0","summary":"5月31日，四川科伦博泰生物医药股份有限公司宣布，其自主研发的抗体偶联药物芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阳性非小细胞肺癌的III期临床研究成果，正式发表于国际医学期刊《柳叶刀》主刊，研究同时入选2026年美国临床肿瘤学会年会口头报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=Hmeug%2Fbu0FE%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4225","BK4211","BK4195","BK4203","BK4231","PFS","BK4080","ADC","HR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639648279","title":"港股异动 | 德琪医药-B(06996)涨超5% ATG-022 ADC治疗相关胃腺癌关键性III期CLINCH-3研究获临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2639648279","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639648279?lang=zh_cn&edition=full","pubTime":"2026-05-29 09:53","pubTimestamp":1780019635,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德琪医药-B涨超5%，截至发稿，涨5.33%，报4.35港元，成交额327.19万港元。消息面上，德琪医药-B发布公告，经中国国家药品监督管理局(药监局)药品审评中心审评，本公司已获药审中心核准同意开展关于ATG-022用于治疗CLDN18.2+晚期胃或胃食管结合部腺癌的关键性III期CLINCH-3研究。本集团无法保证ATG-022最终将成功开发及上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK1191","VXUS","III","BK4588","BK4585","ADC","BK4231","BK1583","BK1574","BK4134","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638687536","title":"艾伯维(ABBV.US)CD123 ADC获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2638687536","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638687536?lang=zh_cn&edition=full","pubTime":"2026-05-28 15:36","pubTimestamp":1779953784,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾伯维宣布美国FDA已经批准其ADC疗法Pivekimab sunirine上市，用于治疗母细胞性浆细胞样树突细胞肿瘤。资料显示，这是全球首个获批上市的CD123 ADC，也是艾伯维首个获批的血液瘤ADC。Pivekimab sunirine是一款靶向CD123的ADC，拟开发用于治疗血液系统恶性肿瘤。CD123靶点在BPDCN肿瘤细胞中呈高度特异性高表达，是该病理想的治疗靶点。美国FDA已于2020年10月授予该药物BPDCN适应症突破性疗法认定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2133065610.SGD","BK4533","IE000BZT7R73.USD","LU2237443465.HKD","IE0000B7K699.USD","IE0002270589.USD","LU1989771016.USD","SG9999015986.USD","ADC","BK4559","BK4080","LU0965509101.SGD","LU1037948897.HKD","IE00B42XCP33.USD","LU1267930573.SGD","LU0158827948.USD","BK4581","LU0289739343.SGD","LU1718418525.SGD","LU0289961442.SGD","LU1244550494.USD","LU1839511570.USD","LU0795875169.SGD","LU0029864427.USD","LU0661504455.SGD","LU1061106388.HKD","BK4566","IPOS","LU0965509010.AUD","LU2089284900.SGD","LU2089984988.USD","SG9999015978.USD","LU0211327993.USD","LU0198837287.USD","LU2357627491.SGD","LU1267930490.SGD","SG9999011175.SGD","LU0820561909.HKD","LU0965509283.SGD","ABBV","IE00BBT3K403.USD","LU1934455277.USD","IE00BVYPNV92.GBP","SG9999003800.SGD","LU0114720955.EUR","LU1023059063.AUD","LU1732799900.SGD","LU0472753341.HKD","LU2237443895.HKD","IE00BLSP4239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638457426","title":"港股异动 | 映恩生物-B(09606)涨超5% 与BioNTech合作开发B7-H3 ADC全球Ⅲ期临床完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2638457426","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638457426?lang=zh_cn&edition=full","pubTime":"2026-05-27 14:56","pubTimestamp":1779864979,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B涨超5%，截至发稿，涨3.14%，报222.6港元，成交额1.52亿港元。消息面上，近日，据映恩生物-B官微消息，公司宣布，与BioNTech SE合作开发的靶向B7-H3的抗体偶联药物DB-1311/BNT324用于治疗未接受过紫杉烷类化疗的转移性去势抵抗性前列腺癌患者的全球Ⅲ期关键性注册临床研究已顺利完成全球首例患者入组给药。2026年5月12日，映恩生物行使独家选择权，参与分摊DB-1311/BNT324在美国地区的研发成本，并共享该药物商业化运营产生的盈亏收益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4080","VXUS","LU2543165471.USD","HK0000252160.HKD","ADC","09606","BK4231","BK4588","HK0000252152.HKD","HK0000500386.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636356678","title":"重磅ADC药物获批多发性骨髓瘤二线联合用药，GSK中国特药业务部负责人：肿瘤是未来GSK重要增长引擎之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2636356678","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636356678?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:41","pubTimestamp":1779176518,"startTime":"0","endTime":"0","summary":"值得注意的是，倍乐锐是GSK肿瘤领域的重磅药物。据GSK全球一季度财报，该药物在今年一季度收入达2300万英镑，在该款药物的加持下，肿瘤业务也已经是GSK当前业绩增长最快的板块。今年第一季度，GSK肿瘤业务销售额同比增长28%，达到5.12亿英镑，业务增速在所有业务中位居第一。GSK副总裁、中国特药业务部负责人张宁向蓝鲸新闻表示，GSK未来会考虑布局更多的ADC药物、小分子药物等形成合力，包括肿瘤在内的特药业务是未来GSK很重要的增长引擎之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1779176429659930072","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU1829250122.USD","BK4231","GSK.UK","BK4007","ADC","GSK","BK4532","BK4588","GSKH","BK4080","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635085638","title":"百亿ADC抗癌药赛道迎新玩家，药企期待多元化支付提高可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=2635085638","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635085638?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:17","pubTimestamp":1778840220,"startTime":"0","endTime":"0","summary":"国内ADC（抗体偶联）领域又迎来重磅选手！近日，葛兰素史克（GSK）宣布，其注射用玛贝兰妥单抗（商品名：倍乐锐）与硼替佐米和地塞米松（BVd）联合用于治疗既往接受过至少一线治疗的多发性骨髓瘤成年患者。该药是目前唯一一个获批用于治疗多发性骨髓瘤的抗B细胞成熟抗原（BCMA）ADC药物，可在多种治疗场景中以30分钟的门诊输注方式满足患者多样化的治疗需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605153739072253.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153739072253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4231","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634629466","title":"百利天恒：iza-bren（EGFR×HER3双抗ADC）获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2634629466","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634629466?lang=zh_cn&edition=full","pubTime":"2026-05-12 17:18","pubTimestamp":1778577480,"startTime":"0","endTime":"0","summary":"南财智讯5月12日电，百利天恒公告，iza-bren（EGFR×HER3双抗ADC）收到国家药品监督管理局《药物临床试验批准通知书》（通知书编号：2026LP01442），同意该药开展联合小分子靶向药物用于治疗驱动基因阳性的局部晚期或转移性非小细胞肺癌的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734555430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4231","91194","688506","ADC","BK0239","02615","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432300","title":"科伦博泰生物(06990)：核心产品TROP2 ADC芦康沙妥珠单抗(sac-TMT) 新增适应症上市申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432300","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633432300?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:16","pubTimestamp":1778235396,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物 发布公告，近日，本公司靶向人滋养细胞表面抗原2 的抗体偶联药物芦康沙妥珠单抗 (佳泰莱)的一项新增适应症上市申请(该申请)已获中国国家药品监督管理局药品审评中心受理。本次受理是基于OptiTROP-Lung05注册3 期研究的积极结果，该申请是芦康沙妥珠单抗获NMPA受理的第五项适应症上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439642.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["ADC","06990","BK4080","LU0196878994.USD","BK4231","BK1161","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629001368","title":"从AACR看中国创新：ADC与双抗领跑 授权交易见证含金量","url":"https://stock-news.laohu8.com/highlight/detail?id=2629001368","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629001368?lang=zh_cn&edition=full","pubTime":"2026-04-23 13:00","pubTimestamp":1776920400,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛1907年的华盛顿，11位医生与科学家随手组建的“小圈子”，谁也没想到会演变成今天全球癌症研究领域最负盛名的盛会——美国癌症研究协会（AACR）。一百多年后的今天，AACR年会早已不只是一场学术会议，更是全球肿瘤研发的“晴雨表”和“风向标”。对中国生物医药产业而言，AACR也成为观察创新活力与国际化进程的最佳窗口。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604233715799065.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233715799065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4080","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629079406","title":"创胜集团医药-B(06628)公布其新型LIV1 ADC TST013在前列腺癌及 ER阳性╱HER2阴性乳腺癌PDX模型中显示出强大的抗肿瘤活性的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629079406","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629079406?lang=zh_cn&edition=full","pubTime":"2026-04-23 07:00","pubTimestamp":1776898849,"startTime":"0","endTime":"0","summary":"智通财经APP讯，创胜集团医药-B 公布，于2026年AACR年会上发表强调其自主研发的LIV1抗体偶联药物的临床前数据。对于LIV1表达的前列腺癌PDX模型，ADC-2在给药两剂后显示出有限的肿瘤生长抑制。总体而言，该等数据证明创胜医药的LIV1 ADC-2及ADC-3项目在ER阳性╱Her2 阴性乳腺癌以及前列腺癌的PDX模型中作为单药疗法显示出强大的抗肿瘤活性。该等结果支持进一步研究创胜医药的LIV1 ADC在LIV1阳性实体瘤中的应用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","BK4231","BK4080","BK1574","PDX","06628","BK1161","BK1515","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629961098","title":"新一代TROP 2 ADC达卓优在华上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2629961098","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629961098?lang=zh_cn&edition=full","pubTime":"2026-04-22 10:13","pubTimestamp":1776823980,"startTime":"0","endTime":"0","summary":"南方财经4月22日电，阿斯利康与第一三共合作开发并引入中国的第二款ADC药物达卓优?（英文商品名:Datroway?，通用名：注射用德达博妥单抗）在中国正式上市，首批到货将陆续在全国各地医院和药房落地启用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223713715630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4080","IPOS","ADC","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629906669","title":"中国生物制药(01177)：礼新医药于AACR 2026公布两款ADC最新研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629906669","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629906669?lang=zh_cn&edition=full","pubTime":"2026-04-22 06:16","pubTimestamp":1776809789,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 公布，该集团全资附属公司礼新医药科技(上海)有限公司自主研发的两款新一代抗体偶联药物 LM-364 “Nectin-4TME ADC”及LM-338 “STn ADC”，于2026年美国癌症研究协会年会公布最新研究数据。LM-364是礼新医药依托自主开发的肿瘤微环境平台开发的新一代Nectin-4TME ADC。目前，LM-364已向美国食品药品监督管理局递交新药临床试验申请，计划于2026年启动首次人体临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","BK1515","09939","ADC","BK1161","BK4080","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","HK0000165453.HKD","BK4231","159938","BK1589","BK1521","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628790385","title":"卡位ADC、TCE前沿赛道，迈威生物(02493)港股IPO含金量有几分？","url":"https://stock-news.laohu8.com/highlight/detail?id=2628790385","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628790385?lang=zh_cn&edition=full","pubTime":"2026-04-20 09:40","pubTimestamp":1776649207,"startTime":"0","endTime":"0","summary":"2026年4月20日，迈威生物正式启动招股程序，中信证券与海通国际担任联席保荐人。在这一波创新药出海浪潮中，手握全球领先管线的迈威生物无疑将受到市场密切关注。通过ADC与TCE双平台驱动，叠加多元化的创新管线布局，迈威生物正在肿瘤治疗领域构建起差异化的强大竞争壁垒。从业绩来看，迈威生物已交出了一份颇具说服力的答卷：2024-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK4080","BK4231","VXUS","SPCX","688062","BK4588","BK4585","02493","ADC","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":-0.0205},{"period":"1month","weight":-0.0312},{"period":"3month","weight":-0.0381},{"period":"6month","weight":0.016},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":0.0169}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agree Realty Corporation成立于1971年，是马里兰州的一家公司。该公司是一家完全整合的房地产投资信托基金，主要专注于净出租给行业领先租户的零售物业的所有权、收购、开发和管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.59375,"avgChangeRate":-0.003579},{"month":2,"riseRate":0.46875,"avgChangeRate":0.002186},{"month":3,"riseRate":0.5625,"avgChangeRate":0.012831},{"month":4,"riseRate":0.59375,"avgChangeRate":0.003425},{"month":5,"riseRate":0.484848,"avgChangeRate":0.013996},{"month":6,"riseRate":0.636364,"avgChangeRate":0.009449},{"month":7,"riseRate":0.65625,"avgChangeRate":0.022845},{"month":8,"riseRate":0.46875,"avgChangeRate":0.002201},{"month":9,"riseRate":0.46875,"avgChangeRate":-0.006321},{"month":10,"riseRate":0.5625,"avgChangeRate":-0.000339},{"month":11,"riseRate":0.65625,"avgChangeRate":0.003584},{"month":12,"riseRate":0.46875,"avgChangeRate":0.00994}],"exchange":"NYSE","name":"艾格里房产","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾格里房产,ADC,艾格里房产股票,艾格里房产股票老虎,艾格里房产股票老虎国际,艾格里房产行情,艾格里房产股票行情,艾格里房产股价,艾格里房产股市,艾格里房产股票价格,艾格里房产股票交易,艾格里房产股票购买,艾格里房产股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}